Grifols, Aradigm sign licensing deal for inhaled ciprofloxacin formulations
Aradigm finished Phase 2b trials in BE patients with Pulmaquin and Lipoquin while the agreement will focus on advancing the candidate into Phase III trials in BE. Grifols
The US Food and Drug Administration (FDA) has declined to approve Unicycive Therapeutics’ resubmitted new drug application (NDA) for oxylanthanum carbonate (OLC) to treat hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.
The company will continue evaluating the compound in other hematologic malignancies such as adult acute lymphoblastic leukemia (ALL). Pfizer’s oncology business unit clinical development and medical affairs senior